Prevymis (letermovir) - Merck (MSD)
cyclophosphamide - Generic mfg.
TCR-αβ/CD 19 Depleted Graft Versus T Replete Graft With Post-Transplant Cyclophosphamide in Children Undergoing Haploidentical Donor Hematopoietic Stem Cell Transplantation for Inborn Errors of Immunity: A Comparative Analysis From India. (PubMed, Pediatr Transplant) - Aug 18, 2026 - "Survival was superior in the T depleted cohort as compared to the T replete group, with viral reactivation remaining a persisting challenge. Letermovir prophylaxis and memory cell add-back would be potential strategies to improve survival." 
Clinical • Journal • Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation
http://www.ncbi.nlm.nih.gov/pubmed/42605147
 
Anuraag Reddy Nalla; Kavitha Ganesan; Krithika Krishnakumar; Minakshi Balwani; Nithya Seshadri; Ramya Uppuluri; Revathi Raj; Vijayshree Muthukumar
 
Aug 18, 2026
 
Prev Next